Tests a GLP-1 drink's effect on gut bacteria and blood sugar in prediabetes
Tests a GLP-1 liquid drink against placebo in adults with prediabetes or obesity.
Plain-language title generated from the registry record
Registry title: Effects of a GLP-1 Formula Drink on Gut Microbiota and Glycemic Control in Prediabetic Individuals
Key facts
- Where
- Taichung, TaiwanSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT07089732, who can take part
Where in Taiwan
- Chung Shan Medical UniversityTaichung, TaiwanNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Chung Shan Medical University
- Trial code
- NCT07089732
- Record updated
- 28 July 2025
- Original description
A clinical human dietary intervention trial was conducted to investigate the effects of GLP-1 FORMUL liquid supplementation in individuals with prediabetes or obesity, with a focus on improvements in glycemic and lipid parameters, body composition, and gut microbiota profiles.Read full original descriptionShow less
Evaluation of the Effects of GLP-1 Formula Liquid Drink on Gut Microbiota Modulation and Blood Glucose Regulation in Prediabetic Populations
A clinical human dietary intervention trial was conducted to investigate the effects of GLP-1 FORMUL liquid supplementation in individuals with prediabetes or obesity, with a focus on improvements in glycemic and lipid parameters, body composition, and gut microbiota profiles.
Inclusion: Adults aged 18 to 70 years; Clinically diagnosed with prediabetes (fasting plasma glucose: 100-125 mg/dL or HbA1c: 5.7-6.4%) or with a body mass index (BMI) of 25-34.9 kg/m², male or female; Have not participated in similar clinical studies within the past three months; Able to comprehend the informed consent form, including the study procedures, potential risks, and benefits, and able to provide written informed consent.
Exclusion: Diagnosed with autoimmune diseases or cancer; Diagnosed with gastrointestinal chronic diseases such as irritable bowel syndrome, inflammatory bowel disease, Crohn's disease, celiac disease, bowel control disorders, fecal incontinence, pancreatitis, peptic ulcer disease, colorectal cancer, short bowel syndrome, ulcerative colitis, lactose intolerance, or chronic diarrhea; History of gastrointestinal surgery; Known allergy or hypersensitivity to probiotics or any of the study product ingredients; History of major psychiatric disorders; History of substance abuse or alcohol dependency; Planning pregnancy in the near future (including male partners), currently pregnant, or breastfeeding women.